Evidence map›Paper›PMID 40098025›Full record

ArticleInfectious diseases of poverty2025

Priority knowledge gaps for schistosomiasis research and development in the World Health Organization Africa Region.

Pauline N Mwinzi, Moses Chimbari, Khadime Sylla, Maurice R Odiere, Nicholas Midzi, Eugene Ruberanziza, Sylvian Mupoyi, Humphrey D Mazigo, Jean T Coulibaly, Uwem Friday Ekpo and 7 more

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Praziquantel Pretreatment ReducesTropical medicine and infectious disease · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Pauline N MwinziExpanded Special Project for Elimination of NTDs, WHO Regional Office for Africa, Brazzaville, Republic of Congo. mwinzip@who.int.ORCID http://orcid.org/0000-0002-3518-2540
Moses ChimbariUniversity of KwaZulu-Natal, College of Health Sciences, Durban, South Africa.
Khadime SyllaUniversite Cheikh Anta Diop, Dakar, Senegal.
Maurice R OdiereCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Nicholas MidziNational Institute of Health Research, Ministry of Health and Childcare, Harare, Zimbabwe.
Eugene RuberanzizaThe END Fund, New York City, NY, USA.
Sylvian MupoyiDepartment of Tropical Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Humphrey D MazigoDepartment of Medical Parasitology and Entomology, School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Jean T CoulibalyFaculty of Biosciences, Félix Houphouët-Boigny University, Abidjan, Côte d'Ivoire.
Uwem Friday EkpoDepartment of Pure and Applied Zoology, Federal University of Agriculture Abeokuta, Abeokuta, Nigeria.
Moussa SackoDepartment of Diagnostic and Biomedical Research, National Institute of Public Health Research, Bamako, Mali.
Sammy M NjengaEastern and Southern Africa Centre of International Parasite Control, Kenya Medical Research Institute, Nairobi, Kenya.
Louis-Albert Tchuem-TchuenteCentre for Schistosomiasis and Parasitology, Yaoundé, Cameroon.
Anouk N GouvrasGlobal Schistosomiasis Alliance, London, UK.
David RollinsonGlobal Schistosomiasis Alliance, London, UK.
Amadou GarbaGlobal NTD Programme, World Health Organization, Geneva, Switzerland.
Elizabeth A JumaExpanded Special Project for Elimination of NTDs, WHO Regional Office for Africa, Brazzaville, Republic of Congo.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Schistosomiasis, also known as bilharzia, is a widespread neglected tropical disease (NTD) in Africa, with more significant research and development (R&D) challenges and gaps compared to other preventive chemotherapy NTDs (PC-NTDs) like onchocerciasis, lymphatic filariasis, and trachoma. In response to this challenge, some global initiatives have advocated for bridging this gap, focusing on coordinated engagement with research donors. In this opinion article we highlight key R&D priorities for combating schistosomiasis in the WHO Africa region. These include defining morbidity indicators, expanding prevention, and developing innovative diagnostics, treatments, and public health strategies like test-and-treat. We emphasize integrating efforts with broader health campaigns, assessing zoonotic transmission through One Health, and using environmental surveillance tools like xenomonitoring and eDNA. We stress the need to study climate and environmental impacts on transmission, zoonotic transmission, schistosome hybridization, and snail ecology, advancing snail control, and developing vaccines, while calling for new treatments beyond praziquantel, addressing drug resistance, and improving access for children and remote populations. Further, operational research should refine hotspot interventions, enhance water, sanitation and hygiene integration, and address socio-cultural barriers. Lastly, sustainable funding and global collaboration are vital to achieve 2030 NTD Roadmap goals.

Indexed as

Biomedical ResearchNeglected DiseasesResearchSchistosomiasisAfricaAnimalsHumansWorld Health OrganizationZoonosesDiagnostic toolsIntermediate snail hostsMass Drug AdministrationMorbidity indicatorsNeglected tropical diseasesOne Health approachPreventive chemotherapySchistosomiasisWater, sanitation and hygieneZoonotic transmission

Identifiers

PMID40098025
PMCPMC11912667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.